INFUSE Morphine Study

Phase 3

Completed

• Conditions: Pain
• Interventions: Drug: Hylenex

• Registration Number: NCT00593281
• Lead Sponsor: Halozyme Therapeutics

Brief Summary

Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this within-patient controlled study, each eligible study patient receives a single injection by each of the three methods of morphine administration, sequentially on three consecutive days, according to the order specified by a randomization schedule.

Each of the three injections consists of 5 mg of morphine (1.0 mL of 5 mg/mL solution). The HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be blinded, the two SC injections will be double-blinded, using the same volume of normal saline (0.9% sodium chloride) placebo (1.0 mL) as HYLENEX.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2006-10
• Study Completion: 2006-10
• Status Verified: 2008-01
• Study First Submitted: 2008-01-02
• Study First Submitted QC: 2008-01-11
• Last Update Submitted: 2008-01-11
• Study First Posted: 2008-01-14
• Last Update Posted: 2008-01-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

1. Males or females at least 18 years of age who are patients of San Diego Hospice & Palliative Care or recruited through San Diego Hospice & Palliative Care or the UCSD Center for Pain and Palliative Medicine.
2. During the treatment days of the study, on opioid therapy other than morphine that is equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.
3. Vital signs (BP, HR, RR) within normal range.
4. Adequate venous access in both upper extremities.
5. A negative pregnancy test (if female of child-bearing potential) within 7 days prior to first injection.
6. Life expectancy ≥ ten days.
7. Decision-making capacity.
8. Signed, written IRB-approved informed consent. -

Exclusion Criteria

1. Known hypersensitivity or history of any toxicity to morphine.
2. Morphine within the 4 days prior to the first study medication injection or anticipated to be receiving morphine during any of the treatment days in this study.
3. Any contraindication to morphine.
4. Known hypersensitivity to naloxone.
5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.
6. Known allergy to bee or vespid venom.
7. Contraindication to IV heparin lock or known hypersensitivity to heparin.
8. Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.
9. Hemoglobin < 10 g/dL.
10. Presence of any other medical condition that would present an unacceptable safety risk to the patient.
11. Participation in a study of any investigational drug or device within 30 days of enrollment in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
3	Hylenex	SC Morphine with Saline
2	Hylenex	SC Morphine with Hylenex

Primary Outcome Measures

Name	Time	Method
• Determine the Tmax and other pharmacokinetic parameters of morphine injected subcutaneously with HYLENEX compared to without HYLENEX and injected intravenously	29 days

Secondary Outcome Measures

Name	Time	Method
Compare the safety and tolerability of these three methods of injections of morphine	29 days

Trial Locations

Locations (2)

UCSD Thornton Hospital; 🇺🇸 San Diego, California, United States

San Diego Hospice and Palliative Care; 🇺🇸 San Diego, California, United States